1. Clinical & Scientific Overview
Clonazepam (TIP-MED-000208, Reference Code [11.4]) is classified under
CNS & Psychiatric Medicines (Ch 11) as a Long-Acting High-Potency Benzodiazepine (GABA-A Receptor Positive Allosteric Modulator; Anticonvulsant & Anxiolytic).
Within the Indian regulatory and compendial framework, it is governed under Schedule H1 Prescription Drug (Mandatory Red-Bordered Rx Warning & 3-Year Register under Rule 65 of Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 11 [11.4], p. 141): Rivotril (Abbott), Zapiz (Intas), Lonazep (Sun Pharma), Clonotril (Torrent), Epitril, Melzap — Strengths & Dosage Forms: Oral Uncoated Scored & Mouth-Dissolving (MD) Tablets: 0.25 mg, 0.5 mg, 1 mg, 2 mg
Oral Uncoated Scored & Mouth-Dissolving (MD) Tablets: 0.25 mg, 0.5 mg, 1 mg, 2 mg
3. Mechanism of Action & Pharmacodynamics
Long-Acting High-Potency Benzodiazepine (GABA-A Receptor Positive Allosteric Modulator; Anticonvulsant & Anxiolytic) acting on target receptor/enzyme pathways in CNS & Psychiatric Medicines (Ch 11): clinical efficacy is mediated via Long-Acting High-Potency Benzodiazepine (GABA-A Receptor Positive Allosteric Modulator; Anticonvulsant & Anxiolytic) for Panic disorder (with or without agoraphobia); focal and generalised epilepsies (myoclonic seizures, absence seizures, Lennox-Gastaut syndrome); REM Sleep Behaviour Disorder (RBD) and severe restless legs syndrome / periodic limb movement disorder; acute short-term anxiety bridge during SSRI initiation..
4. Therapeutic Indications & Evidence-Supported Uses
- Panic disorder (with or without agoraphobia)
- focal and generalised epilepsies (myoclonic seizures, absence seizures, Lennox-Gastaut syndrome)
- REM Sleep Behaviour Disorder (RBD) and severe restless legs syndrome / periodic limb movement disorder
- acute short-term anxiety bridge during SSRI initiation
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Panic / Anxiety Bridge: Initially 0.25 mg to 0.5 mg once daily at bedtime (may titrate to 0.5 mg BD; in elderly: start at 0.125 mg–0.25 mg at bedtime). Epilepsy: Start 0.5 mg twice or three times daily, titrating gradually to 2–4 mg/day. Follow psychiatrist/neurologist prescription.
Administration & Meal Timing: With or without food (MD tablets dissolve directly on the tongue). | At bedtime (10:00 PM) for anxiety/sleep/RBD, or divided 2–3 times daily for epilepsy.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Metabolised hepatically; no formal dose adjustment in mild-to-moderate CKD, but metabolites and sensitivity increase in severe CKD—start at 0.125–0.25 mg. Hepatic: Metabolised by hepatic CYP3A4 and nitroreduction—contraindicated in severe liver disease / cirrhosis (triggers hepatic coma!).
Renal: Metabolised hepatically; no formal dose adjustment in mild-to-moderate CKD, but metabolites and sensitivity increase in severe CKD—start at 0.125–0.25 mg. Hepatic: Metabolised by hepatic CYP3A4 and nitroreduction—contraindicated in severe liver disease / cirrhosis (triggers hepatic coma!).
Renal: Metabolised hepatically; no formal dose adjustment in mild-to-moderate CKD, but metabolites and sensitivity increase in severe CKD—start at 0.125–0.25 mg. Hepatic: Metabolised by hepatic CYP3A4 and nitroreduction—contraindicated in severe liver disease / cirrhosis (triggers hepatic coma!).
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in Severe Respiratory Insufficiency, Severe Obstructive Sleep Apnoea (OSA—relaxes upper airway pharyngeal muscles and suppresses hypoxic ventilatory drive!), Myasthenia Gravis, Acute Narrow-Angle Glaucoma, and Severe Hepatic Failure (precipitates hepatic encephalopathy!).
Key Clinical Precautions: Renal: Metabolised hepatically; no formal dose adjustment in mild-to-moderate CKD, but metabolites and sensitivity increase in severe CKD—start at 0.125–0.25 mg. Hepatic: Metabolised by hepatic CYP3A4 and nitroreduction—contraindicated in severe liver disease / cirrhosis (triggers hepatic coma!).
8. Adverse Effects Profile
- Next-day 'hangover' drowsiness/somnolence (due to long 20–50 hour elimination half-life!), dizziness, ataxia / unsteady gait, psychomotor slowing, anterograde amnesia (memory gaps), hypotonia, increased salivary/bronchial secretions (in high epilepsy doses).
- Hip-fracture falls and traumatic subdural haematoma in the elderly, respiratory depression (especially if combined with opioids or pregabalin, or in COPD/sleep apnoea), paradoxical agitation/disinhibition in elderly dementia patients, physical dependence and withdrawal seizures upon sudden cessation.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Opioids (Tramadol, Morphine, Codeine), Pregabalin, Gabapentin, Zolpidem, Antipsychotics, Tricyclic Antidepressants, Sedating Antihistamines, and Alcohol: Profound synergistic CNS and respiratory depression, coma, and falls! CYP3A4 inhibitors (itraconazole, clarithromycin) slow hepatic metabolism of clonazepam; carbamazepine and phenytoin accelerate its clearance
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: 1. Warn patients that because Clonazepam has a 30-to-40 hour half-life, a bedtime tablet continues to impair reflexes and alertness the next morning—do not drive a two-wheeler or car until certain you are not drowsy! 2. Get out of bed slowly at night when walking to the bathroom. 3. Never stop Clonazepam suddenly if taken daily for more than 2–3 weeks (work with the doctor to reduce by 0.125 mg–0.25 mg every 1–2 weeks).
- Meal & Clock Timing Instruction: With or without food (MD tablets dissolve directly on the tongue). (At bedtime (10:00 PM) for anxiety/sleep/RBD, or divided 2–3 times daily for epilepsy.)
- Missed Dose Protocol: If used for bedtime anxiety/sleep and forgotten, do NOT take it the next morning (causes all-day sedation and driving hazard!). If used 2–3x/day for epilepsy, take as soon as remembered unless close to next dose.
- Geriatric Dispensing Pearl: Beers Criteria Strong Recommendation: Avoid all Benzodiazepines in elderly patients (≥65 years)! In elderly CGHS patients, Clonazepam's 40-hour half-life leads to progressive day-by-day accumulation—presenting after 2–3 weeks as pseudo-dementia (memory loss, slurred speech), daytime somnolence, and devastating hip-fracture falls.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Uncoated Scored & Mouth-Dissolving (MD) Tablets: 0.25 mg, 0.5 mg, 1 mg, 2 mg
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 11 [11.4] (p. 141)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [11.5]-CMP129 Etizolam IP — Short-to-Intermediate Acting Triazolobenzodiazepine (GABA-A Recep
- [11.7]-CMP130 Nortriptyline Hydrochloride & Clomipramine Hydrochloride IP — Tertiary-Amine Tricyclic Antidepressant (TCA; Serotonin & Norepin
- [11.18]-C138 Desvenlafaxine Succinate — Serotonin–Noradrenaline Reuptake Inhibitors (SNRIs)
- [11.19]-CMP139 Fluvoxamine Maleate IP — Selective Serotonin Reuptake Inhibitor (SSRI with Mild Anticholin
